Nuværnede børsværdi: 86mio dkk...

Er der noget, jeg fuldstændigt overser eller er dette en af årets store raketter, der pt. stille og rolig flyver under al opmærksomhed for øjeblikket?

De har netop udsendt denne mail med opsummering og lidt nyt om deres udvikling:

(Disclaimer: Jeg er i aktien og ergo farvet)

1: Focus on US launch
The US partnership with Ventis Pharma will be one of our main priorities in 2024 initiating, the early access program.
A tech transfer of analytical methods has been completed, and sterilized vials and pumps as well as APIs are now available - production will start at the end of this month.
More details during Q1 with first sales expected in Q2.

2: Finalize study 0202
All approvals from authorities are in place for study 0202 to be initiated at the clinical sites. Final contracts and IMP shipment will take place during Q1.
Study 0202 is the remaining safety study in children and will run in selected countries in Europe. We expect recruitment to end during 2H of 2024.

3: Build European partnership
The European market is important for our future setup. We initiated the search for a partner in 2023 and have made very good progress. We aim to have an agreement in place during 2024.
Ideally, we want a partnership structure that can capture the opportunities of CT002 and potential other assets. CT002 will be initiated once this is in place.